Trial Profile
A Phase 1B Study of KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Acute Myeloid Leukemia
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Navtemadlin (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 04 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 04 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 10 Aug 2023 Oral Venetoclax has been added as a primary drug. The procedures of Biospecimen Collection, Bone Marrow Aspiration and Bone Marrow Biopsy have been added to treatments section.